A Hematology Science Researcher’s Experience of the Present Funding Environment

BASIS Phase 3 Trial: Marstacimab Shows Itself a Versatile Hemophilia A, HB Prophylaxis

STArT Trial: Lessons, New Directions for Arginine Studies in Pediatric SCD Vaso-Occlusive Pain

STArT Trial: Arginine as Factor in Pediatric Sickle Cell Disease Vaso-Occlusive Pain

Myeloid Leukemias in SCD: Is Clonal Hematopoiesis the Root?

SPARKLE Assesses Crizanlizumab, Hones Self-Reporting Tech for SCD Pain Care

Sickle Cell Disease: Communication to Improve Clinical Outcomes

Sickle Cell Disease: What Is the Clinical Impact from Misconceptions of this Condition?

Phase 3 Study Evaluates Marstacimab for Hemophilia A, B, Without Inhibitors

Are Knowledge Gaps the Cause of Insufficiencies in HMA-Based MDS Care?

HMA Therapy for MDS in the United States: Is It Optimized?

New Thrombosis Safety Data for RNA Interference Agent to Treat Bleeding Disorders

Clinical Trial’s 13 Years of Follow-Up: Gene Therapy Is Effective, Safe for Hemophilia B

New Era in Sickle Cell Disease: Gene Therapy and the Future of Treatment

How the MIRCA Assay Can Help Guide Treatment Decisions for SCD

Dr. Vivien Sheehan on the Novel MIRCA Assay for SCD

Real-World Database Study Affirms Long-Term Benefit of Hydroxyurea for Anemia in Pediatric SCD

How Is Machine Learning Augmenting Decision Making in Myelofibrosis Care?

ASH Bridge Grant Expands Award Eligibility to Advance Hematology Research

Michael DeBaun, MD, MPH, on Communicating the Meaning of Sickle Cell Trait for Patient Outcomes

Kenneth Adler, MD, Reveals Drivers of Physician Burnout in Hematology, Explores Remedies

Belinda Avalos, MD, Describes ASH’s Efforts to Promote, Hone Diversity Within Hematology

The Role of Inflammation in MDS: What Have Clinical Studies Revealed?

Dr. Amy DeZern on Peripheral Blood Mutation Correlations With Bone Marrow in MDS

How Do Home Socioeconomic Environment Factors Affect SCD Care for Patients?

Dr. Surbhi Sidana Presents Real-World Data Supporting Cilta-Cel for Multiple Myeloma

Assessing the State of Stroke Risk, Prevention in Patients With SCD

Dr. Diesch-Furlanetto on Fertility Considerations With Hydroxyurea in SCD

Dr. Naik on the ASH Hematology-Focused Fellowship Training Program

Academic Mentorships Invigorate the Classical Hematology Profession

Dr. Nausheen Ahmed on the Need to Monitor Infection Risk After CAR-T Therapy

Dr. Steven Romano on Promising Small Interfering RNA Compound Results in PV

How Do Clinicians Choose Pharmacotherapy for Lower-Risk MDS?

How Have the COMMANDS Trial Data Changed Lower-Risk MDS Care?

The Need to Address Nonmalignant Afflictions in Hematology Nursing

Solly Chedid, MD, Describes the Landscape of Upcoming MDS Agents

How Can the Transition From Pediatric to Adult Care in SCD Be Optimized?

Dr. Restrepo: Current Coagulopathy Risk Screening in Venous Malformations May Be Flawed

EHA President-elect Dr. Döhner On the 'Lighting the Flame' Program

Akhila Vadivelan, MD, Discusses Iron Deposition in Transfusion-Dependent SCD

Yaw Ansong-Ansongton, MD, Highlights National Minority Health Month, Celebrate Diversity Month

Erica Mamauag, MD, Finds That FVIII May Be Unnecessary in Tolerized Hemophilia A

Yaw Ansong-Ansongton, MD, on the Impact of Abnormal Mitochondria in Sickled Red Blood Cells

Anjali Sharathkumar, MD, Shares Romiplostim Outcomes in Severe Aplastic Anemia With MDS

Zaina Inam, MD, on Transplant Outcomes in Pediatric Patients With SCD

Real-world Analysis of Pegcetacoplan in PNH with Hemolysis

Michael Grunwald, MD, Highlights Polycythemia Vera for Rare Disease Day

Zahra Pakbaz, MD, on the Challenges of Hematology Patients Swapping From Pediatric to Adult Programs

How Does SCD Impact Brain Growth in Infants?

Zahra Pakbaz, MD, John Strouse, MD, PhD, Discuss Practicing Classical Hematology

Zahra Pakbaz, MD, Describes the Value of a Dedicated Classical Hematology Clinic

Zahra Pakbaz, MD, Defines the Unmet Need for Specialists in Adult Classical Hematology

Gabriela Hobbs, MD, Discusses Updated Data on Ruxolitinib Use During, After Transplant

Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research

Patient-Reported Outcomes, Quality of Life for Luspatercept Versus Epoetin Alfa in MDS

Biomarker Analysis on Inflammatory Effect for Luspatercept Versus Epoetin Alfa in Patients with MDS

Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept

Impact of Molecular Characteristics and Response to Luspatercept in Patients with MDS

Implications of the Full Analysis of the COMMANDS Trial of Luspatercept for MDS

Evolving MDS Treatment Options and the MEDALIST Trial